I’m seeing lots of references to BioWorld’s recent analysis by Cynthia Robbins-Roth showing that U.S.-based, VC-backed biotechs raised $391 million in the first quarter, a 34 percent increase compared to the same period last year. translation
Author Archives: Trista Morrison
Defining Specialty Pharma: What is it, Can it Innovate, and Does it Matter?
March 15, 2012 – 10:46 am
The article I wrote last week for FierceBiotech on the relationship between Series A funding and innovation led to an interesting discussion with Bruce Booth, partner at Atlas Venture and biotech blogger extraordinaire. translation
2010-12 Biotech IPOs Not Performing THAT Bad. Really.
March 12, 2012 – 3:50 pm
What a difference two weeks makes. When I was researching last week’s BioWorld Insight cover – about how emerging biotech Verastem Inc., mature biotech Ironwood Pharmaceuticals Inc. and specialty pharma firm Clovis Oncology Inc. shared some surprising similarities in how…
Licensing or Acquisition? Big Pharma Shares How They (and YOU) Decide
February 8, 2012 – 6:47 pm
When I was at the Biocom Global Life Science Partnering Conference last week, one of the more interesting debates I heard was about whether it’s better to in-license an asset or acquire the whole company. translation
Like Warren Buffett, J&J Throws Down Incubator Gauntlet . . .Who’s Next?
January 19, 2012 – 6:18 pm
When people talk about Johnson and Johnson’s new San Diego incubator, Janssen Labs, they can’t help but be a little bit skeptical about the fact that J&J isn’t taking any options or first-rights to compounds developed by its incubator tenants….
San Diego Scene: Sanford-Burnham Queuing Up Behind J&J to Launch Incubator
January 19, 2012 – 6:11 pm
The San Diego biotech industry has been buzzing this week with the grand opening of Johnson and Johnson’s new incubator, Janssen Labs. But already plans for another San Diego incubator are being laid, this time at the Sanford-Burnham Medical Research…
Five New Trends in Biotech Venture
January 17, 2012 – 6:46 pm
The cover story for BioWorld Insight this week is about the biotech venture capital world, and how despite its much-publicized contraction, there’s a lot of exciting stuff going on like established firms closing new funds, established players regrouping to form…
He Said What?!?! Best Biotech Quotes of 2011
December 29, 2011 – 3:26 pm
As BioWorld Insight readers know, our “Word on the Street” column provides a sample of the most entertaining and thought-provoking quotes our staff stumbles upon each week. Some are gathered during interviews, some gleaned from analyst reports, and some overheard…
BioWorld’s Fifth Annual Biotech Holiday Gift Guide
December 13, 2011 – 7:57 pm
While all you biotechs out there scramble to meet your end-of-year milestones, BioWorld would like to announce a little milestone of our own. That’s right, this is our fifth annual biotech holiday gift guide. translation
Can Other Cell Therapy Firms Avoid Dendreon’s Fate?
December 7, 2011 – 5:43 pm
Stem cell therapies may be relatively early stage, but that hasn’t stopped their developers from giving some serious thought to late stage issues like reimbursement and health economics. translation
Join the Conversation